Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in perinatal delta9-tetrahydrocannabinol occurs in schizophrenia: analyses in patients and in animal model of the disease

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	DI BARTOLOMEO Martina ŠTARK Tibor ORIANA MARIA Maurel IANNOTTI Fabio Arturo KUCHAR Martin RUDÁ Jana PISCITELLI Fabiana LAUDANI Samuele PEKAŘÍK Vladimír SALOMONE Salvatore AROSIO Beatrice MECHOULAM Raphael MACCARRONE Mauro DRAGO Filippo WOTJAK Carsten DI MARZO Vincenzo VISMARA Matteo DELL'OSSO Bernardo D'ADDARIO Claudio MICALE Vincenzo
Year of publication	2021
Type	Article in Periodical
Magazine / Source	PHARMACOLOGICAL RESEARCH
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://www.sciencedirect.com/science/article/pii/S1043661820316650?via%3Dihub
Doi	http://dx.doi.org/10.1016/j.phrs.2020.105357
Keywords	Schizophrenia; THC; Cannabinoid CB1 receptor; Dopamine D2 Receptor; Cannabidiol; DNA methylation; Epigenetics
Description	Reported data add further evidence to the dopamine-cannabinoid interaction in terms of DRD2 and CNR1 dysregulation which could be implicated in the pathogenesis of schizophrenia spectrum disorders, suggesting that cannabidiol treatment may normalize pTHC-induced psychopathology by modulating the altered dopaminergic activity.
Related projects:	Preklinický a klinický výzkum studentů v oblasti farmakokinetiky, neuropsychofarmakologie a personalizované farmakoterapie v onkologii